Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 19 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-ImmunotherapyTerminatedNCT04372927Phase 2Results posted
• AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)CompletedNCT04364620Phase 2Results posted
• Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerCompletedNCT04362072Phase 4Results posted
• A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerActive, not recruitingNCT04351555Phase 3Results posted
• Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment PatternsCompletedNCT04351334Results posted
• Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsCompletedNCT04349267Phase 1/2Results posted
• Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerTerminatedNCT04348292Phase 1Results posted
• Implementation Strategies for Monitoring Adherence in Real TimeActive, not recruitingNCT04347161Not applicableResults posted
• NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT04332653Phase 1/2Results posted
• A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLCTerminatedNCT04325698Phase 3Results posted
• Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsTerminatedNCT04323436Phase 2Results posted
• Trial of NanoPac Intratumoral Injection in Lung CancerCompletedNCT04314895Phase 2Results posted
• TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersCompletedNCT04306900Phase 1Results posted
• Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.CompletedNCT04299048Phase 1Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationActive, not recruitingNCT04280081Phase 2Results posted
• Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentCompletedNCT04256707Phase 1/2Results posted
• Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerActive, not recruitingNCT04250545Phase 1Results posted
• Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyCompletedNCT04249362Phase 2Results posted
• Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedNCT04248829Phase 3Results posted
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
• Resiliency Among Older Adults Receiving Lung Cancer TreatmentCompletedNCT04229381Not applicableResults posted
• A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Active, not recruitingNCT04225117Phase 2Results posted
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 3Results posted
• Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerActive, not recruitingNCT04214262Phase 3Results posted
• The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung CancerCompletedNCT04206787Results posted
• Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsTerminatedNCT04198818Phase 1/2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerActive, not recruitingNCT04194944Phase 3Results posted
• Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesCompletedNCT04181788Phase 1/2Results posted
• The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by OsimertinibCompletedNCT04179890Results posted
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
• KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)CompletedNCT04165096Phase 2Results posted
• A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationTerminatedNCT04165031Phase 1/2Results posted
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTerminatedNCT04161391Phase 1/2Results posted
• EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung CancerCompletedNCT04159025Not applicableResults posted
• Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)CompletedNCT04155541Results posted
• Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%TerminatedNCT04139317Phase 2Results posted
• Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung CancerCompletedNCT04120454Phase 2Results posted
• Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving OsimertinibTerminatedNCT04099836Phase 2Results posted
• Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLCTerminatedNCT04081688Phase 1Results posted
• A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04075396Phase 1/2Results posted
• CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerActive, not recruitingNCT04062708Phase 2Results posted
• Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT04051827Phase 1Results posted
• A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesCompletedNCT04042558Phase 2Results posted
• Exhaled Breath Analysis to Predict Risk of Symptomatic PneumonitisTerminatedNCT04040244Not applicableResults posted
• Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 TherapyTerminatedNCT04037462Phase 1/2Results posted
• A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingNCT04035486Phase 3Results posted
• ATL001 in Patients With Advanced Unresectable or Metastatic NSCLCTerminatedNCT04032847Phase 1/2Results posted
• A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsTerminatedNCT04032704Phase 2Results posted
• Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung CancerActive, not recruitingNCT04032418Phase 2Results posted
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04027946Phase 2Results posted
• A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results posted
• A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerActive, not recruitingNCT04025879Phase 3Results posted
• Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung CancerCompletedNCT04012619Phase 1Results posted
• Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung CancerCompletedNCT04003246Phase 2Results posted
• Metabolic and Microbial Profiling of Lung CancerTerminatedNCT03998189Not applicableResults posted
• Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone MetastasesTerminatedNCT03996473Phase 1Results posted
• Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/2Results posted
• National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLCCompletedNCT03982459Not applicableResults posted
• Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorCompletedNCT03977467Phase 2Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)CompletedNCT03976375Phase 3Results posted
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Phase 1/2Results posted
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)CompletedNCT03971474Phase 2Results posted
• This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.TerminatedNCT03968419Phase 2Results posted
• BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in BelgiumCompletedNCT03959137Results posted
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension StudyCompletedNCT03950674Phase 3Results posted
• A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)TerminatedNCT03948763Phase 1Results posted
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2Results posted
• Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerActive, not recruitingNCT03939481Results posted
• Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)TerminatedNCT03924869Phase 3Results posted
• Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerCompletedNCT03916419Phase 2Results posted
• An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerCompletedNCT03915951Phase 2Results posted
• A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaCompletedNCT03909971Phase 2Results posted
• Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 ImmunotherapyTerminatedNCT03904108Phase 2Results posted
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
• Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesTerminatedNCT03881488Phase 1Results posted
• A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension StudyCompletedNCT03875092Phase 3Results posted
• Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung CancerTerminatedNCT03871153Phase 2Results posted
• High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung CancerTerminatedNCT03870529Early Phase 1Results posted
• Osimertinib Study in Indian PatientsCompletedNCT03853551Phase 4Results posted
• Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension StudyCompletedNCT03850444Phase 3Results posted
• A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsStatus unknownNCT03849768Phase 3Results posted
• Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung CancerCompletedNCT03847519Phase 1/2Results posted
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results posted
• M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT03840915Phase 1/2Results posted
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)TerminatedNCT03840902Phase 2Results posted
• Atezolizumab Plus Bevacizumab in First Line NSCLC PatientsCompletedNCT03836066Phase 2Results posted
• Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK ResistanceCompletedNCT03833934Results posted
• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03831932Phase 1/2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)CompletedNCT03829332Phase 3Results posted
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedNCT03822351Phase 2Results posted
• Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC PatientsCompletedNCT03812549Phase 1Results posted
• A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung CancerActive, not recruitingNCT03807778Phase 1Results posted
• Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene FusionsTerminatedNCT03805841Phase 2Results posted
• Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedNCT03794544Phase 2Results posted
• This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedNCT03780725Phase 1Results posted
• Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingNCT03778229Phase 2Results posted
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung CancerTerminatedNCT03745222Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2CompletedNCT03743064Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1CompletedNCT03743051Phase 3Results posted

← Carcinoma, Non-Small-Cell Lung overview